The changing face of metabolic syndrome and its components in the light of current knowledge

Current Vascular Pharmacology

Volumn 12, Issue 4, 2014, Pages 549-

  Ertek, Sibel ^a   Banach, Maciej ^b  

^a Department of Endocrinology and Metabolism ^*  (Turkey)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular disease; Metabolic syndrome

Indexed keywords

BODY MASS; CARDIOVASCULAR RISK; DYSLIPIDEMI; EDITORIAL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; METABOLIC SYNDROME X; BLOOD; COMPLICATION; DYSLIPIDEMIA; LIFESTYLE; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

DYSLIPIDEMIAS; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM; STRESS, PSYCHOLOGICAL;

EID: 84904723325     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111204140702101134     Document Type: Editorial

References (52)

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-9.
2. Athyros VG, Giouleme O, Ganotakis ES, et al. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci 2011; 7: 796-805.
3. Ertek S, Cicero AF, Cesur M, et al. The severity of coronary atherosclerosis in diabetic and non-diabetic metabolic syndrome patients diagnosed according to different criteria and undergoing elective angiography. Acta Diabetol 2011; 48: 21-7.
4. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic Syndrome: definitions and controversies. BMC Med 2011; 9: 48.
5. Barylski M, Kowalczyk E, Banach M, Ciecwierz J, Pawlicki L, Kowalski J. Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology 2009; 60: 87-92.
6. Ismail NA, Ragab S, El Dayem SM, et al. Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci 2012; 8: 826-33.
7. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease. Int J Cardiol 2013; 164(2): 141-50.
8. St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arteriosclerol Thromb Vasc Biol 2005; 25: 553-9.
9. Toth PP. Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease. Curr Vasc Pharmacol 2014; 12(4): 653-57.
10. Nicholls SJ, Andrews B, Duong M. Controversies on HDL: Should it be a target biomarker in patients with lipid disorders? Curr Vasc Pharmacol 2014; 12(4): 649-52.
11. Otocka-Kmiecik A, Mikhailidis DP, Nicholls SJ, Davidson M, Rysz J, Banach M. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease? Prog Lipid Res 2012; 51: 314-24.
12. Filippatos TD, Elisaf MS. Recommendations for severe hypertriglyceridemia treatment, are there new strategies? Curr Vasc Pharmacol 2014; 12(4): 598-616.
13. Seneff S, Wainwright G, Mascitelli L. Is the metabolic syndrome caused by a high fructose, and relatively low fat, low cholesterol diet? Arch Med Sci 2011; 7: 8-20.
14. Michalska M, Zanchetti A, Wong ND, Malyszko J, Rysz J, Banach M. Patients with prehypertension-do we have enough evidence to treat them? Curr Vasc Pharmacol 2014; 12(4): 586-97.
15. Cicero AF, Tartagni E, Ertek S. Nutraceuticals for metabolic syndrome management: from laboratory to benchside. Curr Vasc Pharmacol 2014; 12(4) 565-71.
16. Katsiki N, Athyros G, Karagiannis A, Mikhailidis D. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Curr Vasc Pharmacol 2014; 12(4): 627-41.
17. Stpie M, Wlaze RN, Paradowski M, et al. Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo-and hypertensive patients-pilot study. Arch Med Sci 2012; 8: 431-6
18. Stepien M, Rosniak-Bak K, Paradowski M, et al. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med Sci Monit 2011; 17: PR13-8.
19. Rizzo M, Obradovic M, Labudovic-Borovic M, et al. Uric acid metabolism in pre-hypertension and the metabolic syndrome. Curr Vasc Pharmacol 2014; 12(4): 572-85.
20. Malyszko J, Banach M. Pre-CKD-Do we Need Another Hero? Curr Vasc Pharmacol 2014; 12(4): 642-48.
21. Lewington S, Clarke R, Qizilbash N. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a metaanalysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
22. Zhang W, Li N. Prevalence, risk factors, and management of prehypertension. Int J Hypertens 2011; 2011: 605359.
23. Banach M, Aronow WS. Blood pressure j-curve: current concepts. Curr Hypertens Rep 2012; 14: 556-66.
24. Julius S, Nesbitt SD, Egan BM, et al. Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006; 354: 1685-97.
25. Lüders, S, Schrader J, Berger J, et al. PHARAO Study Group. The PHARAO study: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens 2008; 26: 1487-96.
26. Ertek S, Cetinkalp S. Is there U-turn from insulin back to pills in diabetes? Curr Vasc Pharmacol 2014; 12(4): 617-26.
27. Origin Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. N Engl J Med 2012; 367: 319-28.
28. Olszanecka-Glinianowicz M, Koceak P, Nylec M, Chudek J, Zahorska-Markiewicz B. Circulating visfatin level and visfatin/insulin ratio in obese women with metabolic syndrome. Arch Med Sci 2012; 8: 214-8.
29. Stepien M, Stepien A, Wlazel RN, et al. Predictors of Insulin Resistance in Patients With Obesity: A Pilot Study. Angiology 2014; 65(1): 23-30.
30. De la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2008; 2: 1101-13.
31. Cetinkalp S, Simsir IY, Ertek S. Insulin Resistance in Brain and Possible Therapeutic Approaches. Curr Vasc Pharmacol 2014; 12(4) 553-64.
32. Cicero AF, D'Addato S, Veronesi M, et al. Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study. J Hypertens 2012; 30: 492-6.
33. Prandin MG, Cicero AF, Dormi A, et al. Prospective evaluation of the effect of statins on blood pressure control in hypertensive patients in clinical practice. Nutr Metab Cardiovasc Dis 2010; 20: 512-8.
34. Katsiki N, Mikhailidis DP, Banach M. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens 2011; 29: 2493-4.
35. Owczarek J, Jasiska M, Wejman I, Kurczewska U, Orszulak-Michalak D. Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocholesterolaemic and normotensive rats. Arch Med Sci 2012; 8: 17-21
36. Rizzo M, Montalto G, Banach M. The effects of statins on blood pressure: current knowledge and future perspectives. Arch Med Sci 2012; 8: 1-3.
37. Stepien M, Banach M, Mikhailidis DP, Gluba A, Kjeldsen SE, Rysz J. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009; 25: 1995-2005.
38. Banach M, Nikfar S, Rahimi R, et al. Lipid and Blood Pressure Meta-Analysis Collaboration Group. The effects of statins on blood pressure in normotensive or hypertensive subjects-A meta-analysis of randomized controlled trials. Int J Cardiol 2013; 168(3): 2816-24.
39. Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR, Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of newonset diabetes among 19, 257 patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care 2008; 31: 982-8.
40. Lee WY, Kwon CH, Rhee EJ, et al. The effect of body mass index and fasting glucose on the relationship between blood pressure and incident diabetes mellitus: a 5-year follow-up study. Hypertens Res 2011; 34: 1093-7.
41. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
42. The NAVIGATOR Study Group. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. N Eng J Med 2010; 362: 1477-90.
43. Shabnam AA, Homa K, Reza MT, Bagher L, Hossein FM, Hamidreza A. Cut-off points of waist circumference and body mass index for detecting diabetes, hypercholesterolemia and hypertension according to National Non-Communicable Disease Risk Factors Surveillance in Iran. Arch Med Sci 2012; 8: 614-21.
44. Huising MO, van der Meulen T, Vaughan JM, et al. CRFR1 is expressed on pancreatic beta cells, promotes beta cell proliferation, and potentiates insulin secretion in a glucose-dependent manner. Proc Natl Acad Sci USA 2010; 107: 912-7.
45. Pedersen BK. The diseasome of physical inactivity and the role of myokines in muscle-fat cross-talk. J Physiol 2009; 587: 5559-68.
46. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exercise Immunol Rev 2006; 12: 6-33.
47. Ostrowski K, Schjerling P, Pedersen BK. Physical activity and plasma IL-6 levels in humans: effect of intensity of exercise. Eur J Appl Physiol 2000; 83: 512-5.
48. Ertek S, Cicero A. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Arch Med Sci 2012; 8: 794-804.
49. Gollasch M. Vasodilator signals from perivascular adipose tissue. Br J Pharmacol 2012; 165: 633-42. 50.
50. Mikhailidis DP, Elisaf MS, Rizzo M, et al. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses. Curr Vasc Pharmacol 2011; 9: 533-71.
51. Mikhailidis DP, Elisaf MS, Rizzo M, et al. "European Panel on Low Density Lipoprotein (LDL) Subclasses": A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses: Executive Summary. Curr Vasc Pharmacol 2011; 9: 531-2.
52. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.